Russian Recruits Show 'No Side Effects' in Chinese Coronavirus Vaccine Trials

The immunization is the so-called "whole-virion" vaccine, based on a destroyed or artificially weakened virus particle which is incapable of causing a disease.

According to the government official, most laboratories and countries developing the vaccine claim that the first doses are expected to be available in the first quarter of next year, as had been reported to the population.

EpiVacCorona, another Russian vaccine designed by the Vektor State Research Center of Virology and Biotechnology, is now in the process of registration.

South Korea is pushing to secure enough coronavirus vaccines to be administered to 30 million people, or 60 percent of the country's population, and plans to secure 20 percent of the vaccines through participation in the COVAX Facility. That will face a critical test in coming weeks, as investors await clinical data on whether they actually work.

"Nasabi natin yung mga need natin na matanggap na (we were able to tell them what we need) so we can already start with the process of regulation and start the clinical trial the soonest time possible", Vergeire said.

"One of our requests to them is the clinical trial protocol that we are waiting for before our vaccine experts panel starts its study for the conduct of clinical trial for Sputnik V", Vergeire said.

Kingsville high school reports COVID-19 case: GECDSB
Conseil Scolaire Catholique Providence, the French-language Catholic board, reported a case Friday at L'Essor Secondary School in Tecumseh.

Coronavirus vaccine news, update: Last week Director-General of Indian Council of Medical Research (ICMR) Balram Bhargava told media, "Russia has been manufacturing vaccines for many years". Coronavirus vaccine: A look at Moderna and AstraZeneca-Oxford University vaccine candidates. Phase III trials, involving at least 40,000 people, are ongoing in Russian Federation. Regarding the Russian Vaccine, a high-level committee of the Government of India is in dialogue with Russia.

Yevgenia Zubova, a spokesperson for the Moscow city health department, said in an interview that the vaccine was available only to trial participants.

However, on September 15, the DCGI gave permission to the SII to resume clinical trial of the vaccine.

COVAX will bring the richer countries together with 92 low- and middle-income economies such as the Philippines and Indonesia, which are eligible for support for the procurement of vaccines through the Gavi COVAX Advance Market Commitment (AMC), a financing instrument.

"It has now been accepted that Russia's approach is the correct one", he said in a statement after reports emerged that the U.S. Food and Drug Administration might provide an emergency use approval for a vaccine, an idea promoted by President Donald Trump. The FDA found a lower percentage of trials with problems in Russian Federation than in any other European country or the United States.